5 Articles found
MDxHealth Articles
-
Assessment of a urinary TRUS/biomarker-based risk score as inclusion criteria for multiparametric MRI to detect clinically significant prostate cancer
BACKGROUND Non-invasive techniques like urinary biomarkers and multiparametric Magnetic Resonance Imaging (mpMRI) show great promise for the detection of clinically significant prostate cancer (PCa), leading to a reduction of over-diagnosis ...
-
Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men.
Organizations Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, MDxHealth, B.V., Nijmegen, Netherlands, MDxHealth, Inc., Irvine, CA, Mathematical Modeling, Statistics and ...
-
Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men
Abstract Objective: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior ...
-
Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment
Abstract Purpose: SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. In this study we sought to ...
-
Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies
Abstract Background: Prostate cancer (PCa) diagnosis is challenging because efforts for effective, timely treatment of men with significant cancer typically result in over-diagnosis and repeat biopsies. The presence or absence of epigenetic ...